Compare AHMA & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | AYTU |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 25.7M |
| IPO Year | N/A | 2015 |
| Metric | AHMA | AYTU |
|---|---|---|
| Price | $1.33 | $2.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 6.4M | 37.5K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.76 | $1.00 |
| 52 Week High | $39.50 | $3.07 |
| Indicator | AHMA | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 31.12 | 52.49 |
| Support Level | $0.76 | $2.46 |
| Resistance Level | $8.47 | $2.66 |
| Average True Range (ATR) | 0.19 | 0.12 |
| MACD | 0.33 | -0.01 |
| Stochastic Oscillator | 56.88 | 50.87 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.